MannKind FY2025 EPS Estimate Increased by Cantor Fitzgerald

MannKind Co. (NASDAQ:MNKD - Free Report) - Investment analysts at Cantor Fitzgerald increased their FY2025 earnings per share estimates for MannKind in a report issued on Monday, May 12th. Cantor Fitzgerald analyst O. Brayer now forecasts that the biopharmaceutical company will earn $0.23 per share for the year, up from their previous estimate of $0.18. The consensus estimate for MannKind's current full-year earnings is $0.10 per share.

MannKind (NASDAQ:MNKD - Get Free Report) last posted its quarterly earnings data on Thursday, May 8th. The biopharmaceutical company reported $0.04 earnings per share for the quarter, topping the consensus estimate of $0.03 by $0.01. The firm had revenue of $78.35 million during the quarter, compared to analysts' expectations of $75.86 million. MannKind had a net margin of 8.07% and a negative return on equity of 17.74%. MannKind's revenue was up 18.1% on a year-over-year basis. During the same quarter in the previous year, the company posted $0.05 EPS.

Several other brokerages also recently issued reports on MNKD. Mizuho initiated coverage on MannKind in a report on Thursday, April 10th. They issued an "outperform" rating and a $12.00 price target for the company. StockNews.com raised shares of MannKind from a "hold" rating to a "buy" rating in a research report on Wednesday, March 19th. Finally, Wedbush reissued an "outperform" rating and set a $11.00 price target on shares of MannKind in a research report on Thursday, February 27th. Seven research analysts have rated the stock with a buy rating and two have given a strong buy rating to the company's stock. According to MarketBeat, MannKind has a consensus rating of "Buy" and a consensus target price of $10.00.

MannKind Stock Up 1.7%

NASDAQ MNKD traded up $0.08 on Wednesday, reaching $4.45. The company had a trading volume of 536,083 shares, compared to its average volume of 2,377,136. The stock's 50 day moving average is $4.84 and its 200-day moving average is $5.74. The stock has a market cap of $1.35 billion, a price-to-earnings ratio of 63.50 and a beta of 1.14. MannKind has a 52 week low of $4.34 and a 52 week high of $7.63.

Insider Transactions at MannKind

In related news, EVP David Thomson sold 32,179 shares of the company's stock in a transaction that occurred on Tuesday, May 13th. The shares were sold at an average price of $4.68, for a total transaction of $150,597.72. Following the completion of the transaction, the executive vice president now directly owns 772,427 shares in the company, valued at $3,614,958.36. This represents a 4.00% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Steven B. Binder sold 80,144 shares of the stock in a transaction dated Tuesday, May 13th. The shares were sold at an average price of $4.69, for a total value of $375,875.36. Following the completion of the transaction, the director now owns 1,006,611 shares of the company's stock, valued at $4,721,005.59. This represents a 7.37% decrease in their ownership of the stock. The disclosure for this sale can be found here. 2.70% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of MNKD. Arrowstreet Capital Limited Partnership raised its position in shares of MannKind by 275.9% during the fourth quarter. Arrowstreet Capital Limited Partnership now owns 4,887,609 shares of the biopharmaceutical company's stock worth $31,427,000 after acquiring an additional 3,587,484 shares during the last quarter. Nuveen LLC acquired a new stake in shares of MannKind during the 1st quarter worth approximately $17,011,000. Millennium Management LLC lifted its holdings in shares of MannKind by 68.9% in the first quarter. Millennium Management LLC now owns 5,822,590 shares of the biopharmaceutical company's stock valued at $29,288,000 after purchasing an additional 2,375,198 shares in the last quarter. Graham Capital Management L.P. purchased a new position in MannKind during the fourth quarter worth about $10,229,000. Finally, Vanguard Group Inc. boosted its position in MannKind by 7.9% in the first quarter. Vanguard Group Inc. now owns 17,322,179 shares of the biopharmaceutical company's stock worth $87,131,000 after purchasing an additional 1,263,622 shares during the last quarter. 49.55% of the stock is owned by institutional investors.

MannKind Company Profile

MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes, and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults.